AIM: To examine psychological distress in women at risk of familial breast-ovarian cancer (FBOC) or hereditary non-polyposis colorectal cancer (HNPCC) with absence of demonstrated mutations in the family (unknown mutation). MATERIALS AND METHODS: Two-hundred and fifty three consecutive women at risk of FBOC and 77 at risk of HNPCC and with no present or past history of cancer. They were aware of their risk and had received genetic counseling. Comparisons were made between these two groups, normal controls, and women who were identified to be BRCA1 mutation carriers. The questionnaires Beck Hopelessness Scale (BHS), General Health Questionnaire (GHQ-28), Hospital Anxiety and Depression Scale (HADS) and Impact of Event Scale (IES) were employed to assess psychological distress. RESULTS: No significant differences concerning psychological distress were observed between women with FBOC and women with HNPCC. Compared to mutation carriers for BRCA1, the level of anxiety and depression was significantly higher in the FBOC group with absence of demonstrated mutation. Compared to normal controls, the level of anxiety was higher, while the level of depression was lower in the groups with unknown mutation. CONCLUSIONS: Women in the absence of demonstrated mutations have higher anxiety and depression levels than women with known mutation-carrier status. Access to genetic testing may be of psychologically benefit to women at risk for FBOC or HNPCC.
AIM: To examine psychological distress in women at risk of familial breast-ovarian cancer (FBOC) or hereditary non-polyposis colorectal cancer (HNPCC) with absence of demonstrated mutations in the family (unknown mutation). MATERIALS AND METHODS: Two-hundred and fifty three consecutive women at risk of FBOC and 77 at risk of HNPCC and with no present or past history of cancer. They were aware of their risk and had received genetic counseling. Comparisons were made between these two groups, normal controls, and women who were identified to be BRCA1 mutation carriers. The questionnaires Beck Hopelessness Scale (BHS), General Health Questionnaire (GHQ-28), Hospital Anxiety and Depression Scale (HADS) and Impact of Event Scale (IES) were employed to assess psychological distress. RESULTS: No significant differences concerning psychological distress were observed between women with FBOC and women with HNPCC. Compared to mutation carriers for BRCA1, the level of anxiety and depression was significantly higher in the FBOC group with absence of demonstrated mutation. Compared to normal controls, the level of anxiety was higher, while the level of depression was lower in the groups with unknown mutation. CONCLUSIONS:Women in the absence of demonstrated mutations have higher anxiety and depression levels than women with known mutation-carrier status. Access to genetic testing may be of psychologically benefit to women at risk for FBOC or HNPCC.
Authors: B Meiser; P Butow; M Friedlander; A Barratt; V Schnieden; M Watson; J Brown; K Tucker Journal: Eur J Cancer Date: 2002-10 Impact factor: 9.162
Authors: Pål Møller; Ake Borg; D Gareth Evans; Neva Haites; Marta M Reis; Hans Vasen; Elaine Anderson; C Michael Steel; Jaran Apold; David Goudie; Anthony Howell; Fiona Lalloo; Lovise Maehle; Helen Gregory; Ketil Heimdal Journal: Int J Cancer Date: 2002-10-20 Impact factor: 7.396
Authors: Amy Østertun Geirdal; Lovise Maehle; Ketil Heimdal; Astrid Stormorken; Pål Møller; Alv A Dahl Journal: Qual Life Res Date: 2006-04 Impact factor: 4.147
Authors: Cathrine Bjorvatn; Geir Egil Eide; Berit R Hanestad; Anniken Hamang; Odd E Havik Journal: Support Care Cancer Date: 2009-02-18 Impact factor: 3.603
Authors: Alice Woo; Amit Sadana; David T Mauger; Maria J Baker; Terri Berk; Thomas J McGarrity Journal: Fam Cancer Date: 2008-07-05 Impact factor: 2.375
Authors: Karin M Landsbergen; Judith B Prins; Han G Brunner; Floris W Kraaimaat; Nicoline Hoogerbrugge Journal: Fam Cancer Date: 2009-03-28 Impact factor: 2.375